CR
CRDF.O
—
NASDAQ
Pharmaceuticals & Medical Research
MKDWELL Tech Inc
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
62,9M USD
P/E
—
EV / Rev
—
Div yield
—
Op margin
-8 256,3 %
ROE
-101,0 %
Net margin
-7 732,0 %
Debt / equity
0,00
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
$0,87
Open
$0,89
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About
MKDWELL Tech Inc is a biotechnology company focused on pharmaceuticals and medical research, generating revenue primarily through the development and commercialization of biotech products.
Business. MKDWELL Tech Inc (NASDAQ: CRDF.O) is a biotechnology and medical research company operating within the healthcare sector. The firm engages in pharmaceuticals and medical research activities, generating revenue through product sales. Specific details regarding operating segments and geographic presence are not available. The company is primarily listed on the NASDAQ stock exchange.
Classification99 %
SectorHealth Care
Industry groupPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
BUY8 analysts
4 buy4 hold0 sell
Avg 12m price target7,50
Analyst recommendations
8 analysts · consensus BuyBuy4
Hold4
Sell0
12-month price target
7,50
Consensus of sell-side coverage.
At a glance
Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Buy
8 analysts · indicative
Ownership→
Nuveen LLC
largest disclosed fund holder
Profitability→
-101,0 %
return on equity
Quality
—
not yet scored
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
0Sector rotation
Sector1D1Mvs mkt
Materials+2,3 %+6,6 %+1,7 %
Communication Services+2,2 %−5,5 %+1,7 %
Energy+0,6 %+3,3 %+0,0 %
Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
Consumer Discretionary+0,4 %+7,7 %−0,2 %
Information Technology+0,3 %+7,8 %−0,3 %
Financials−0,3 %−2,8 %−0,9 %
Consumer Staples−0,4 %+2,5 %−1,0 %
Real Estate−0,7 %+10,9 %−1,3 %
Industrials−1,9 %−3,1 %−2,5 %
Utilities−1,9 %+28,2 %−2,5 %
Developing storylines
No tracked sagas currently linked to CRDF.O. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-08-04
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
— missing data
Signals & dispatch
peak dispatch · —
Composite-score breakdown
Synthesis
Business
MKDWELL Tech Inc (NASDAQ: CRDF.O) is a biotechnology and medical research company operating within the healthcare sector. The firm engages in pharmaceuticals and medical research activities, generating revenue through product sales. Specific details regarding operating segments and geographic presence are not available. The company is primarily listed on the NASDAQ stock exchange.
Classification99 %
SectorHealth Care
Industry groupPharmaceuticals & Medical Research
AI synthesis
GENERATEDMKDWELL Tech Inc has a market capitalization of $109.4 million and a price-to-book ratio of 2.41, indicating that the market values the company at a premium to its book value. The company's liquidity position is characterized by a current ratio of 3.67, suggesting a strong ability to meet short-term obligations, supported by $17.5 million in cash and equivalents. However, the company has no long-term debt, which reduces its leverage and financial risk.
The company's profitability is currently negative, with a net loss of $45.9 million and an operating loss of $48.96 million, resulting in a return on equity of -101.02% and a return on assets of -74.09%. These figures are significantly below the industry median for profitability metrics, indicating that MKDWELL Tech Inc is underperforming its peers in terms of generating returns.
MKDWELL Tech Inc's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of diversification may expose the company to higher risk if its primary market or product line experiences a downturn.
The company's growth trajectory is uncertain, with no specific revenue growth projections provided in the available data. The company's operating cash flow is negative at -$37.92 million, and its free cash flow is also negative at -$45.56 million, indicating that it is not generating sufficient cash from operations to fund its activities. The company's capital expenditure of -$44,000 is minimal, suggesting limited investment in growth initiatives.
The risk assessment for MKDWELL Tech Inc indicates low liquidity and dilution risks, with no immediate filing-based liquidity or dilution flags detected. The company's dilution potential is low, as there is no difference between basic and diluted shares outstanding, and no recent issuance or shelf registration activity is reported.
Recent events and filings do not indicate any significant changes in the company's operations or financial position. The company's price targets from analysts range from $3.50 to $12.00, with a mean of $8.57 and a median of $10.00, suggesting a generally positive outlook despite the company's current financial challenges.
Key takeaways
- MKDWELL Tech Inc is a biotechnology company with a market capitalization of $109.4 million and a price-to-book ratio of 2.41.
- The company is currently unprofitable, with a net loss of $45.9 million and an operating loss of $48.96 million.
- MKDWELL Tech Inc has a strong liquidity position with a current ratio of 3.67 and $17.5 million in cash and equivalents.
- The company's revenue is concentrated in a single business segment, with no geographic diversification provided in the available data.
- Analysts have a generally positive outlook on the company, with price targets ranging from $3.50 to $12.00.
- "margin_outlook_rationale": "The company's current negative net and operating margins indicate a lack of profitability, which is a concern for future margin stability.",
Bull / Bear case
Generated · model-assisted— missing data
In focus — financials by report
Valuation
Market price
$0,92
Market cap
$109.4M
Enterprise valueⓘ
$91.9M
P/Eⓘ
—
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
—
EV / Op incomeⓘ
—
EV / OCFⓘ
—
P / Bⓘ
2.4x
P / Tangible bookⓘ
2.4x
Tangible book
$45.4M
Net cashⓘ
$17.5M
Current ratioⓘ
3.7
Debt / equityⓘ
0.0
ROAⓘ
-74.1%
ROEⓘ
-1.0%
Cash conversionⓘ
83.0%
CapEx / revenueⓘ
-7.4%
SBC / revenueⓘ
—
Dilution ratioⓘ
0.0%
Revenue by segment
Business relationships
Business relationships1 disclosed relationship · 1 type · extracted from filings & disclosures
Partners1
Pfizer IncPFE.TOPartner95%Source ↗
Supply chain
Vendors → CRDF ↔ Partners → Customers · click any node to drill
1 mention in 10-K0 from corporate websites0 from news dispatches
Updated 2026-07-17Peer comparison
Peer comparison8 peers · vs CRDF · multiples and returns
KL
KLAR—
KLAR.ST
—
—P/E
—
— vs self
Div yield
—
— vs self
ROE
—
— vs self
BN
BNTX—
Biontech SE
$92,25
23,3B USDP/E
—
— vs self
Div yield
—
— vs self
ROE
—
— vs self
EX
EXEL—
Exelixis Inc
$55,06
14,7B USDP/E
19,5x
— vs self
Div yield
—
— vs self
ROE
40,4 %
+172,5 vs self
MD
MDGL—
Madrigal Pharmaceuticals Inc
$482,00
11,0B USDP/E
—
— vs self
Div yield
—
— vs self
ROE
-47,8 %
+84,3 vs self
IN
INSM—
Insmed Inc
$107,46
23,0B USDP/E
—
— vs self
Div yield
—
— vs self
ROE
-160,2 %
-28,1 vs self
VC
VCYT—
Veracyte Inc
$45,54
3,6B USDP/E
55,5x
— vs self
Div yield
—
— vs self
ROE
5,1 %
+137,2 vs self
MD
MDXG—
Mimedx Group Inc
$4,27
636,0M USDP/E
11,1x
— vs self
Div yield
—
— vs self
ROE
18,9 %
+151,0 vs self
AV
AVIR—
Atea Pharmaceuticals Inc
$4,62
—P/E
—
— vs self
Div yield
—
— vs self
ROE
-57,5 %
+74,6 vs self
Market position
Stress test
— missing data
Predictor forecast
Next quarternear-term
Earnings · next quarterconf 38 %
EPS
Consensus EPS
-0,67
Predicted surprise
-0,07
Beat probability
38 %
Analysts
8
Other metrics
Revenue
—
no estimate
Segment revenue
—
no estimate
Margin
—
no estimate
Segment margin
—
no estimate
revision ratio -0,14 · as of 2026-07-17 · Earnings Surprise V1
Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
Full fiscal year~1 year ahead
Full fiscal year · our forecast vs guidance vs consensus
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -0,67 |
| Revenue | —no estimate | —no estimate | 277,880 USD |
| Operating income | —no estimate | —no estimate | -50,9M USD |
Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
Probabilistic model output — not investment advice. · generated 2026-08-04
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Consensus distribution
sell-side coverageRecommendation distribution8 analysts
Strong buy1
Buy3
Hold4
Sell0
Strong sell0
12-month price target$7,50 · Median $7,50
Low $2,00High $12,00
Operating income · consensus-50,9M USD
EPS surprise
−2,8 %
reported vs consensus · miss
Revenue surprise
+113,4 %
reported vs consensus · beat
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
Low$2,00
Mean$7,50
Median$7,50
High$12,00
Spot$0,92
+715.0 %implied to mean12-month sell-side price targets · ▲ spot
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskLow
Liquidity riskLow
Filing-based flags
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Op Margin-8 256,3 %Bottom quartile
Net Margin-7 732,0 %Bottom quartile
ROE-101,0 %Bottom quartile
Capex / Rev-7,4 %Bottom quartile
D/E0,00Above median
Cash Conv0,83Above median
Corporate actions / M&A
— missing data
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
Derivative transactions
Net acquired 2 389 475 sh11 grants10 insiders
- Director · Stock Options → Common StockAcquired 40 565 @ $1,59grant · 2026-06-11
- Director · Stock Options → Common StockAcquired 40 565 @ $1,59grant · 2026-06-11
- Director · Stock Options → Common StockAcquired 40 565 @ $1,59grant · 2026-06-11
- Director · Stock Options → Common StockAcquired 40 565 @ $1,59grant · 2026-06-11
- Director · Stock Options → Common StockAcquired 40 565 @ $1,59grant · 2026-06-11
- Chief Operating Officer · Stock Options → Common StockAcquired 400 000 @ $1,72grant · 2026-04-27
- Chief Scientific Officer · Stock Options → Common StockAcquired 300 000 @ $1,63grant · 2026-04-14
- Chief Financial Officer · Stock Options → Common StockAcquired 486 650 @ $1,58grant · 2026-04-06
- Director, Chief Executive Officer · Stock Options → Common StockAcquired 600 000 @ $1,62grant · 2026-03-31
- Director, Interim CEO · Stock Options → Common StockAcquired 200 000 @ $1,56grant · 2026-02-17
- Chief Accounting Officer · Stock Options → Common StockAcquired 200 000 @ $1,60grant · 2026-02-13
Actions
Ask Handelsavisen
— missing data
Data sources
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
How metrics are computed
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Ev To Revenueenterprise_value / revenue
Source documents
- MKDWELL Tech Inc Market data — financials · 2026-05-27
- Cardiff Oncology Inc Market data — analyst estimates · 2026-05-27
Ownership & reference
Top holders
- Investment Managers · as of 2024-12-310,00 %$3M
- Investment Managers · as of 2026-03-310,00 %$2M
- Investment Managers · as of 2026-03-310,00 %$3M
- Investment Managers · as of 2025-12-310,00 %$10M
- Investment Managers · as of 2024-06-300,00 %$6M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$1M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$2M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Brokerage Firms · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Brokerage Firms · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Funds · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
Leadership
- Mani MohindruPresident, Chief Executive Officer, Director
Insider activity
Net buying2 buys · 0 sellsnet $66K2 insiders · last 365d
- Director, Chief Executive Officer · Common StockBought 24 703 @ $1,21$30K · 2026-06-18
- Director · Common StockBought 30 000 @ $1,22$37K · 2026-06-18
Short positioning
12.1Mshares short-5.7% vs prior
6.16days to cover
74.2%short of daily vol
5.3Kfails-to-deliver
as of 2026-07-15 · short-interest report (free)
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
CRDF.OCanonical
NASDAQ · USD
Intel & risk
peak dispatch · —
OSINT findings
Dilution riskLow
Liquidity riskLow
No immediate filing-based liquidity or dilution flags were detected.
Relationship graph
This companySectorPartners
Evidence & claims
From filings & derived data- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -66.1%Derived (calculated)
- Net margin (FY 2025-12-31): -7.7%Derived (calculated)
- Return on equity (FY 2025-12-31): -0.1%Derived (calculated)
- Return on assets (FY 2025-12-31): -0.1%Derived (calculated)
- Current ratio (FY 2025-12-31): 3.67xDerived (calculated)
- Debt-to-equity (FY 2025-12-31): 0.36xDerived (calculated)
- Capex (YoY) (2025-12-31 vs 2024-12-31): -45.0%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 27.4%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 27.4%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): -0.9%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -0.6%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): -0.6%Derived (calculated)
- Revenue (YoY) (2025-12-31 vs 2024-12-31): -13.2%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -45.3%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): -36.3%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 15.8%Derived (calculated)
- Total operating expenses (annual): USD 49.55MSEC XBRL filing
- Net income (annual): USD -45.85KSEC XBRL filing
- Current liabilities (annual): USD 16.39MSEC XBRL filing
- Capex (annual): USD 44KSEC XBRL filing
- Shareholders' equity (annual): USD 45.39MSEC XBRL filing
- Operating cash flow (annual): USD -37.92MSEC XBRL filing
- Cash & equivalents (annual): USD 17.47MSEC XBRL filing
- Total liabilities (annual): USD 16.5MSEC XBRL filing
Showing 24 of 60 surfaced claims.
Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.
The Thread
Everything we know, in order2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
2026-08-04 00:00 UTCTRANSCRIPTEarnings call — Q3 2026
2026-07-15 21:49 UTCEVENTHa Price Listing CRDF price below 1 ($0.8861) — US continued-listing minimum-bid threshold
2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
2026-06-20 00:43 UTCANALYSTAnalyst coverage initiated
2026-06-20 00:43 UTCANALYSTAnalyst coverage initiated
2026-06-20 00:43 UTCANALYSTAnalyst coverage initiated
2026-06-20 00:43 UTCANALYSTAnalyst coverage initiated
2026-06-18 00:00 UTCINSIDER7 insider transactions — 2026-06 5 derivative
2026-06-18INSIDERMohindru Mani bought 24.7k sh — Director, Chief Executive Officer ~$30k
2026-06-18INSIDERPACE GARY W bought 30.0k sh — Director ~$37k
2026-06-11INSIDERArmitage James O acquired 40.6k sh Stock Options — Director
2026-06-11INSIDERWhite Lale acquired 40.6k sh Stock Options — Director
2026-06-11INSIDERTANNENBAUM RENEE P acquired 40.6k sh Stock Options — Director
2026-06-11INSIDERMarkin Rodney S acquired 40.6k sh Stock Options — Director
2026-06-11INSIDERPACE GARY W acquired 40.6k sh Stock Options — Director
2026-04-27 00:00 UTCINSIDER3 insider transactions — 2026-04 3 derivative
2026-04-27INSIDERAggarwal Ajay acquired 400.0k sh Stock Options — Chief Operating Officer
2026-04-14INSIDERSmeal Tod acquired 300.0k sh Stock Options — Chief Scientific Officer
2026-04-06INSIDERMuntner Joshua B acquired 486.6k sh Stock Options — Chief Financial Officer
2026-03-31 00:00 UTCINSIDER1 insider transaction — 2026-03 1 derivative
2026-03-31INSIDERMohindru Mani acquired 600.0k sh Stock Options — Director, Chief Executive Officer
2026-02-17 00:00 UTCINSIDER2 insider transactions — 2026-02 2 derivative
2026-02-17INSIDERMohindru Mani acquired 200.0k sh Stock Options — Director, Interim CEO
2026-02-13INSIDERLindsay Brigitte Ute acquired 200.0k sh Stock Options — Chief Accounting Officer
2025-07-30 00:00 UTCINSIDER2 insider transactions — 2025-07 · net buy $710k
2025-06-26 00:00 UTCINSIDER6 insider transactions — 2025-06 6 derivative
2025-03-11 00:00 UTCINSIDER1 insider transaction — 2025-03 1 derivative
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04
Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data
Premium coverage